Hundreds of health workers in the state of South Australia will undergo a clinical trial to test whether an established tuberculosis vaccine can be used to reduce the severity of the novel coronavirus symptoms by providing a boost to the immune system.
According to the ABC science news, the South Australian Health and Medical Research Institute (SAHMRI) has been researching the effects of the vaccine known as the Bacille Calmette-Guerin vaccine (BCG), for some time.
Almost 250 health workers will be given the vaccine and 250 others will be given a placebo.
Researchers will study if an established tuberculosis vaccine could provide an immune system boost to reduce the prevalence or severity of COVID-19 symptoms, it said.
SAHMRI Executive Director Steven Wesselingh, on Saturday said while the vaccine was designed to protect against tuberculosis and also used as a common treatment for bladder cancer patients, it had also helped boost immunity against other infections.
"Trial participants, who will be randomly allocated to either receive the vaccine or be in a control group, will be monitored for symptoms and receive testing where indicated," he said.
"The trial will provide key evidence that could prove invaluable in both the current fight against COVID-19 and future novel viral outbreaks," he said.
Wesselingh said the BCG vaccine could also boost human "front line" immunity, which trains the immune system to respond to germs with "greater intensity".
The state government has injected 200,000 Australian dollars (USD 126,977) for the clinical trial and SAHMRI along with Murdoch Children's Research Institute (MCRI) has partnered together to roll out the trial with the support of the World Health Organisation.
"It is very exciting that this existing vaccine could make a real difference to the health and wellbeing of our hospital staff on the front lines of the fight against COVID-19," state Health Minister Stephen Wade said.
"The nature of their work means healthcare workers are at increased risk of contracting COVID-19, so it is important that they are first to be able to access this potentially protective intervention," Wade said.
Meanwhile, Australia's number of fatalities from COVID-19 rose to 56 after an octogenarian died in the state of Victoria on Friday.
The number of confirmed cases in the country has reached 6,298.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
